Therefore, amalgamating immune checkpoint inhibitors (such as PD-1/PD-L1 blockers) with VEGFR-2 inhibitors prevents tumor-associated macrophages and other pro-angiogenic immune cells from supporting resistance (Shigeta et al. 2020) and has shown promise in clinical trials (Chen et al. 2024b). Here, KDR is linked to neoplasm.